USFDA grants approval to Zydus Cadila for drug to treat schizophrenia
DSIJ Intelligence / 23 Aug 2017
In a filing with the BSE, Zydus Cadila has stated that it has received final approval from the USFDA to market Ziprasidone Hydrochloride Capsules in strengths of 20 mg, 40 mg, 60 mg and 80 mg.
In a filing with the BSE, Zydus Cadila has stated that it has received final approval from the USFDA to market Ziprasidone Hydrochloride Capsules in strengths of 20 mg, 40 mg, 60 mg and 80 mg. This is an anti-psychotic medication used to treat schizophrenia and manic symptoms of bipolar disorder (manic depression), the company said.
The drug will be manufactured at the group’s formulations manufacturing facility at the Pharma SEZ, Ahmedabad. The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04, it added.
Cadila Healthcare was trading at Rs 464.50 per share, down by Rs 3.90 or 0.83% as at 1159 hours on Wednesday, on the BSE. It attracted a traded volume of 4,13,720 shares and traded value of Rs 1,927.11 lakhs on the NSE.